Clinicians need to address maternal health at all stages, with some seeing a possible new role for GLP-1 drugs.

The results show dose-dependent LDL-lowering and, in contrast to what was seen previously with VERVE-101, no safety issues.

Though ischemic outcomes numerically favored the Amulet, confirmation in future studies is needed, experts say.

The ABCVM wanted to certify cardiologists outside of ABIM, but the recent denial doesn’t mean their efforts have stopped.

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

The dynamic field of advanced heart failure, and helping these patients live comfortably, has inspired this fellow.

For every 100,000 runners who complete the full 42.2 km distance, there will be one cardiac arrest, new data show.

The transition from adolescence can bring decreased physical activity, a worse diet, and little focus on overall CV health.

There’s room on the market for new TAVI valves as long as they can compete with the best in practice, a researcher says.

The study is the latest showing that it doesn’t matter how exercise gets done in a week, as long as it gets done.

The drug was approved last year for patients with hypertension currently not controlled on other BP-lowering agents.

The system, which has received CE Mark approval in Europe, adds to an increasingly crowded field of PFA technologies.